WTO proposal to waive COVID vaccine IP rights puts pandemic response at risk, says EFPIA

18 March 2022
efpia-big-2

Following the release of a draft text for the World Trade Organization (WTO)-led waiver on intellectual property (IP) for COVID-19 vaccines, the European Federation of Pharmaceutical Industries and Associations (EFPIA) calls on governments across Europe and around the world to urgently rethink discussions on a COVID vaccine waiver and instead focus on the real barriers to global vaccine equity.

Commenting on its release, EFPIA’s director general Nathalie Moll said: “The draft proposal from the WTO completely undermines the very research-ecosystem that gave us vaccines to protect citizens against COVID-19. It seeks to solve a vaccine production issue that no longer exists, while at the same time, diverts attention and urgently needed effort away from the real barriers to global vaccine equity.”

Since it was first proposed in 2020, the lack of international consensus, immediate concerns over the effectiveness and negative impact of the proposal meant it was soon overtaken by events. Industry increased capacity to be able to produce over 1 billion doses a month and continuous investment in manufacturing together with 371 licensing agreements meant reaching the milestone of 12 billion doses by January 2022.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical